Ledger Gazette |
US FDA Approves GSK Asthma Drug
ObserverLeader.com (blog) The U.S. Food and Drug Administration has given the green light to the use of mepolizumab (produced under the name Nucala by GlaxoSmithKline) as treatment in severe cases of asthma for patients of 12 years or older with an eosinophilic phenotype. FDA approves Mepolizumab for maintenance treatment of severe asthma Nucala approved to treat severe asthma Nucala: FDA Approves GSK Drug for Severe Asthma |
View full post on asthma – Google News